NICE nixes AstraZeneca's Lynparza; Faes sets China marketing deal; Sanofi faces ERISA suit over alleged kickbacks;

> England's cost-effectiveness gatekeepers at the National Institute for Health and Care Excellence rejected AstraZeneca's ($AZN) new ovarian cancer drug Lynparza in preliminary guidance, saying it costs too much for the benefits it provides. Release | Report

> Spain's Faes Farma inked a deal with Chinese drugmaker Eddingpharma on a joint venture that will market products in China, beginning with four of Faes' drugs. Report

> A combo of two Genentech drugs, Perjeta and Herceptin, helped breast cancer patients live longer without their disease recurring compared with Herceptin plus chemo. Story

> Stockholders in Sanofi's ($SNY) group savings plan allege that the plan's administrators violated retirement plan laws by providing misledaing information about the company's alleged kickbacks to doctors, subject of a whistleblower lawsuit. Report

And Finally... Doctors are growing increasingly impatient with cancer drug shortages. Report

Suggested Articles

Only months removed from a gamechanging label expansion for Vascepa, Amarin is scrambling after a district judge invalidated the drug's key patents.

Move over, Roche. There’s a new small-cell lung cancer therapy on the scene, and it belongs to AstraZeneca.

Gilead CEO promised to make remdesivir affordable, shortly after the company backed off its request for orphan status amid a public backlash.